The osteoporosis drugs market is expected to grow with a CAGR of 3.4% during the forecast period, 2022-2027.
Many therapies are being followed around the world to find reliable COVID-19 treatments. Numerous studies have suggested that in addition to drugs used to treat infections, other drugs such as the drug osteoporosis may be helpful in the treatment of COVID-19, which may grow the market. For example, according to a study published in November 2020 "General treatment of osteoporosis may help reduce the incidence of COVID-19", treatments such as denosumab, zoledronate, and calcium, are used to treat osteoporosis, may protect against COVID-19. The study was conducted by Pompeu Fabra University, Hospital del Mar Medical Research Institute (IMIM), and Pere Virgili Health Park. According to research, treatment with osteoporosis can lead to a reduction in COVID-19 infection by 30 to 40 percent. Therefore, the studied market is likely to see a positive impact of COVID-19.
A major factor that allows market growth is an increase in the incidence of osteoporosis. According to the study "Spread and experience of diagnosing osteoporosis in postmenopausal women over the age of 50: Focus on social issues" published in March 2021, the prevalence of osteoporosis was 34.8%, with a diagnosis rate of 22.1% in South Korea's highest. The increase in the number of young people worldwide who are prone to bone growth is another important factor in market growth. For example, according to information published by the International Osteoporosis Foundation in 2020, 1 in 5 men and 1 in 3 women, over the age of 50, may experience osteoporosis fractures in their remaining global life.
In addition, the growing investment in research and development by biotechnology and pharmaceutical companies is enhancing market growth. For example, in October 2020, the Italian pharmaceutical authority approved the testing of human clinics with raloxifene, a standard orthopedic drug that researchers hope could also help reduce the symptoms of COVID-19 and make patients less likely to become infected. Therefore, positive results from clinical trials can lead to new treatment options, thus boosting future market growth. However, strict government regulations are major barriers to market growth.
Key Market Trends
The RANK Ligand Inhibitors Segment is Expected To Dominate the Market Over the Forecast Period
RANK ligand (RANKL) inhibitors are used to treat osteoporosis in patients at high risk of fracture. The high growth potential achieved is the result of the positive patient outcomes associated with rank ligand inhibitors. Positive patient outcomes can be attributed to significant improvements in bone metabolism. Rank ligand inhibitors can also be used in combination with other drugs to convey the synergistic effect on the entire treatment system. The above-mentioned factor is also expected to be one of the key factors that should be addressed in order to generate profit potential. Other benefits associated with rank ligand inhibitors are a reduction in cellular bone density and an increase in bone mineral density, thus involving greater demand.
The RANK ligand may act as prophylaxis of COVID-19. According to a study conducted at Del Mar Hospital, a Spanish hospital by 2020, denosumab aims for the RANK / RANKL system, which is involved in maintaining balance in the skeletal system. It is involved in the development of lymph nodes T-cell activation and also affects the immune system. Inhibition of this system reduces cytokines that cause inflammation in the body and helps control inflammation, which is one of the major risk factors for COVID-19. Thus, due to the widespread use of RANKL, the segment is likely to grow at a rapid rate.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America is expected to dominate the overall osteoporosis drugs market throughout the forecast period. The market growth is due to the factors such as the presence of key players, the high prevalence of osteoporosis patients in the region, established healthcare infrastructure, and the availability of branded drugs.
In the North American region, the United States has the largest market share due to factors such as increasing the adult population, the growing number of patients in the country, and several collaborative efforts initiated by large companies to improve their capabilities and ensure higher medical standards. For example, according to information published by the National Osteoporosis Foundation (NOF) since 2020, more than 10 million people in the United States have been diagnosed with osteoporosis, which is more common in menopause. Therefore, the increase in incidence due to menopause in women is expected to be a significant growth factor contributing to the regional drug market for osteoporosis.
COVID-19 disrupts and delays the treatment of many patients with osteoporosis; hence, the American Society for Bone and Mineral Research (ASBMR) set up an orthopedic orthopedic committee to oversee the treatment of targeted diseases during the epidemic. For example, in April 2020, a paper on the evidence behind the recommendations was published in the official journal of the American Society for Bone and Mineral Research (ASBMR), Journal of Bone and Mineral Research. The guidelines recommend that patients should continue with osteoporosis medication if possible to do so safely, and that the introduction of new oral bisphosphonate treatment can be done remotely and should not be delayed in patients at high risk of fracture. Therefore, COVID-19 is expected to have a major impact on regional market growth.
The growing demand is also predicted to be the result of collaborative research programs implemented by major health organizations and companies and the development of new products that constantly strive to improve alternative therapies in the current market environment. For example, in 2019, Amgen announced that the US Food and Drug Administration had approved its Evenity (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women who are at high risk for fracture (fracture). This may open the way for growth in the regional market.
The osteoporosis drugs market is moderately competitive and consists of several major players. Some of the companies currently dominating the market are Pfizer Inc., Eli Lily and Company, F. Hoffmann La Roche, Merck & Co. Inc., Amgen Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd, GlaxoSmithKline PLC, Novartis International AG, and Actavis PLC. This industry is anticipated to witness intense competition during the forecast period as a consequence of the rising incorporation of collaborative strategies among the key players to sustain in the competitive position. The other strategies incorporated are high R&D investments, mergers and acquisitions, and agreements for drug development.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Incidences of Osteoporosis
4.2.2 Rise in the Geriatric Populations
4.3 Market Restraints
4.3.1 Stringent Regulatory Environment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 Parathyroid Hormone Therapy
5.1.4 RANKL Inhibitors
5.1.5 Other Drug Types
5.2 By Application
5.2.1 Primary Osteoporosis
5.2.2 Secondary Osteoporosis
5.3.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.3.5 South America
126.96.36.199 Rest of South America
6.1.1 Pfizer Inc.
6.1.2 Eli Lily and Company
6.1.3 F. Hoffmann La Roche
6.1.4 Merck & Co. Inc.
6.1.5 Amgen Inc.
6.1.6 Radius Health Inc.
6.1.7 Teva Pharmaceutical Industries Ltd
6.1.8 GlaxoSmithKline PLC
6.1.9 Novartis International AG
6.1.10 Actavis PLC
A selection of companies mentioned in this report includes:
- Pfizer Inc.
- Eli Lily and Company
- F. Hoffmann La Roche
- Merck & Co. Inc.
- Amgen Inc.
- Radius Health Inc.
- Teva Pharmaceutical Industries Ltd
- GlaxoSmithKline PLC
- Novartis International AG
- Actavis PLC